Aug 20 2024 3 mins
Provider Insights on the Impact of 340B Pricing.
We frequently get asked for insights on how the 340B Drug Pricing Program may... or may not... be impacting the prescribing choices of participating covered entities. The Health Resources and Services Administration (HRSA) administers this federal program which is intended to help safety-net providers carry out their missions to serve their communities.
The Kinetix Group (TKG) recently conducted a market access research study to gain insights from healthcare providers on how the 340B program is impacting care delivery in covered entities. You can reach out to us for the full study, but a few of the highlights from our study are included in this briefing
You can download the full Executive Briefing at: https://tkgpact.com/executive-briefings/
Or, feel free to email us at [email protected]